
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
In this week’s Pointers With Portela, the 208SkinDoc asks consumers skin health and skin care trivia questions about adequate sleep, SPF reapplication, melasma, and more.
In his most recent YouTube episode,
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Dr Portela's social media channels:
YouTube:
2.
3.
Instagram:
Twitter:






